"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
| Descriptor ID |
D015497
|
| MeSH Number(s) |
B04.820.650.589.650.350.400
|
| Concept/Terms |
HIV-1- HIV-1
- Human immunodeficiency virus 1
- HIV-I
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
|
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in this website by year, and whether "HIV-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 6 | 2 | 8 |
| 1997 | 5 | 0 | 5 |
| 1998 | 10 | 1 | 11 |
| 1999 | 4 | 3 | 7 |
| 2000 | 6 | 1 | 7 |
| 2001 | 9 | 2 | 11 |
| 2002 | 16 | 3 | 19 |
| 2003 | 3 | 3 | 6 |
| 2004 | 9 | 4 | 13 |
| 2005 | 3 | 3 | 6 |
| 2006 | 14 | 4 | 18 |
| 2007 | 10 | 2 | 12 |
| 2008 | 10 | 2 | 12 |
| 2009 | 7 | 5 | 12 |
| 2010 | 12 | 4 | 16 |
| 2011 | 8 | 4 | 12 |
| 2012 | 12 | 4 | 16 |
| 2013 | 12 | 3 | 15 |
| 2014 | 9 | 5 | 14 |
| 2015 | 8 | 5 | 13 |
| 2016 | 10 | 7 | 17 |
| 2017 | 10 | 1 | 11 |
| 2018 | 10 | 8 | 18 |
| 2019 | 4 | 3 | 7 |
| 2020 | 8 | 5 | 13 |
| 2021 | 3 | 2 | 5 |
| 2022 | 6 | 0 | 6 |
| 2023 | 10 | 1 | 11 |
| 2024 | 7 | 2 | 9 |
| 2025 | 4 | 1 | 5 |
| 2026 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey. J Int AIDS Soc. 2026 May; 29(5):e70108.
-
Selective elimination of myeloid HIV reservoirs by targeting pro-survival pathways. J Infect. 2026 May; 92(5):106733.
-
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. J Antimicrob Chemother. 2026 Mar 04; 81(4).
-
Elimination of Human Immunodeficiency Virus Reservoirs Harboring Intact Proviruses. J Infect Dis. 2026 Feb 18; 233(2):267-277.
-
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20?years, in Sub-Saharan Africa. Contemp Clin Trials. 2026 Mar; 162:108213.
-
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity. J Virol. 2025 12 23; 99(12):e0125625.
-
Effects of sex but not race and geographic origin on vaccine-induced HIV-specific antibody responses. Front Immunol. 2025; 16:1601865.
-
The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig. AIDS Res Hum Retroviruses. 2025 12; 41(12):567-579.
-
Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life. Nature. 2025 09; 645(8082):1020-1028.
-
Apollo: a comprehensive GPU-powered within-host simulator for viral evolution and infection dynamics across population, tissue, and cell. Nat Commun. 2025 Jul 01; 16(1):5783.